Therapeutically, targeting the NLRP3/caspase-1 pathway significantly reduces cytokine release and ameliorates glomerulosclerosis and proteinuria, emerging as a core target for mitigating GM-driven inflammation in DN (67, 76). The gene discussed is NLRP3; the disease is liver dysplastic nodule.